Klaas Poelstra
Corporate Officer/Principal en University of Groningen .
Perfil
Dr. Klaas Poelstra is Chief Scientific Officer at BiOrion Technologies BV and a Principal at University of Groningen.
Cargos activos de Klaas Poelstra
| Empresas | Cargo | Inicio |
|---|---|---|
| University of Groningen | Corporate Officer/Principal | 21/08/2009 |
Antiguos cargos conocidos de Klaas Poelstra.
| Empresas | Cargo | Fin |
|---|---|---|
BiOrion Technologies BV
 BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Fundador | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Klaas Poelstra
